Document:

Exhibit 10.22

 

NEITHER
THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. THIS DEBENTURE DOES NOT REQUIRE PHYSICAL SURRENDER HEREOF IN ORDER TO EFFECT
A PARTIAL PAYMENT, REDEMPTION OR CONVERSION HEREOF. ACCORDINGLY, THE OUTSTANDING PRINCIPAL AMOUNT OF THIS DEBENTURE MAY BE LESS
THAN THE PRINCIPAL AMOUNT SHOWN BELOW.

 

VIRAL GENETICS, INC.

 

5% UNSECURED CONVERTIBLE DEBENTURE

 

	San Marino, California	 	$250,000.00
	Issue Date: July 1, 2010	 	 

 

FOR VALUE RECEIVED,
VIRAL GENETICS, INC., a Delaware corporation (the "Company"), hereby promises to pay to the order of Vincent
J. Davitt, an individual or its permitted successors or assigns (the "Holder") the sum of two-hundred and fifty
thousand dollars ($250,000.00) in same day funds, on or before June 30, 2011 (the "Maturity Date"). The Holder
may convert amounts of this Debenture into shares ("Conversion Shares") of the Company's common stock, par value
$0.0001 per share (the "Common Stock"), on the terms and subject to the conditions set forth herein.

 

The Company has issued
this Debenture in full satisfaction of invoices payable to Holder, copies of which are attached hereto, and which represent all
amounts, liabilities and claims owed by Company to Holder as of the date hereof (the "Owed Amounts").

 

The Company's obligations
under the Debenture, including without limitation its obligation to make payments of principal thereof and interest thereon, are
unsecured.

 

The following terms shall apply to this Debenture:

 

1. DEFINITIONS.

 

"Applicable
Interest Rate" means an annual rate equal to five percent (5%), computed on the basis of a 360-day year and calculated
using the actual number of days elapsed since the Issue Date or the date on which Interest was most recently paid, as the case
may be, and compounded monthly.

 

"Conversion
Price" means the closing market price of the Company's common shares on the date of conversion as reported by www.pinksheets.com
multiplied by 0.9.

 

"Default
Interest Rate" means twelve percent (12%).

    	1

    	 

    

 

 

"Issue
Date" means the date on which this Debenture is issued.

 

"Maturity
Date" has the meaning set forth in the preamble to this Agreement.

 

"Person"
means any individual, corporation, trust, association, company, partnership, joint venture, limited liability company,
joint stock company, governmental authority or other entity.

 

All definitions contained in this Debenture are equally applicable
to the singular and plural forms of the terms defined. The words "hereof', "herein" and "hereunder" and
words of similar import referring to this Debenture refer to this Debenture as a whole and not to any particular provision of
this Debenture.

 

2.PAYMENT.

 

(a)            
Principal Payment. The Company shall pay to the Holder, in cash on or before the Maturity Date, the original principal
amount of this Debenture (plus unpaid accrued interest thereon); provided, that if the Maturity Date is not a business
day, such payment shall be made on the next succeeding business day. The Principal Payment that is due in cash and which is not
paid on the Maturity Date shall bear interest until paid at the Default Interest Rate.

 

(b)           
Interest Accrual. This Debenture shall bear interest on the unpaid principal amount hereof ("Interest")
at the Applicable Interest Rate. The Company shall pay accrued and unpaid Interest on the Maturity Date and on any date
on which the entire principal amount of this Debenture is paid in full (each referred to herein as an "Interest Payment
Date").

 

(c)            
Interest Payments. The Company shall pay Interest in cash by wire transfer of immediately available funds. Interest
that is due in cash and which is not paid within thirty (30) business days of the applicable Interest Payment Date shall bear interest
until paid at the Default Interest Rate.

 

(d)           
Prepayment. The Company may prepay the unpaid principal and accrued interest of this Debenture in whole or in part
at any time by delivery in immediately-available cash following 2 business days advance notice in writing.

 

3.CONVERSION_

 

(a)          
Right to Force Conversion. Subject to the conditions and limitations specifically provided herein, Company may elect
at its sole discretion to require the Holder to convert, at any time and from time to time after the Issue Date, all or any part
of the outstanding and unpaid principal amount and accrued interest of this Debenture into such number of Shares as is determined
in accordance with the terms hereof (a "Conversion").

 

    	2

    	 

    

 

(b)          Conversion
Notice. In order to require a conversion of principal and accrued interest of this Debenture, the company shall send to
Holder by facsimile transmission, at any time prior to 5:00 p.m., Pacific Time, on the business day on which the Company
wishes to effect such Conversion (the "Conversion Date"), a properly completed notice of
conversion, in the form set forth on Annex I hereto, stating the amount of principal (and, if the Company so elects,
Interest) to be converted and a calculation of the number of Shares issuable upon such Conversion (a "Conversion
Notice"). The Holder may specify the name or names (if not the Holder) in which the Shares that are issuable on
such Conversion shall be issued by notifying Company within 24 hours by facsimile transmission. The Holder shall not be
required to physically surrender this Debenture to the Company in order to effect a Conversion, unless such Conversion would
represent payment in full of the Debenture. The Company shall maintain a record showing, at any given time, the unpaid
principal amount of this Debenture and the date of each Conversion or other payment of principal hereof.

 

(c)              
Number of Shares; Conversion Price. The number of Shares to be delivered by the Company pursuant to a Conversion
shall be equal to the principal amount of (and, if the Company so elects, Interest accrued on) this Debenture being converted divided
by the Conversion Price.

 

(d)             
Delivery of Common Stock Upon Conversion. Upon delivery of a Conversion Notice, the Company shall, no later than
the close of business on the fifth (5th) business day following the Conversion Date set forth in such Conversion Notice
(the "Delivery Date"), issue and deliver or cause to be delivered to the Holder the number of shares of
common stock ("Shares") determined pursuant to paragraph 3(c) above. The Company shall effect delivery
of the Shares to the Holder no later than the close of business on such Delivery Date by delivering to the Holder or its nominee
physical certificates representing such shares. If any Conversion would create a fractional share, such fractional share shall
be disregarded and the number of shares issuable upon such Conversion, in the aggregate, shall be the nearest whole number.

 

4.MISCELLANEOUS.

 

(a)            
Failure to Exercise Rights not Waiver. No failure or delay on the part of the Holder in the exercise of any power,
right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right
or privilege preclude any other or further exercise thereof. All rights and remedies of the Holder hereunder are cumulative and
not exclusive of any rights or remedies otherwise available.

 

(b)           
Notices. Any notice, demand or request required or permitted to be given by the Company or the Holder pursuant to
the terms of this Debenture shall be in writing and shall be deemed delivered (i) when delivered personally or by verifiable facsimile
transmission, unless such delivery is made on a day that is not a business day, in which case such delivery will be deemed to be
made on the next succeeding business day and (ii) on the next business day after timely delivery to an overnight courier, addressed
as follows:

 

If to the Company:

 

Viral Genetics, Inc.

2210 Huntington Drive, Suite 100

San Marino, CA 91108

Attn: Haig Keledjian, Chief Executive Officer

Tel: 626-334-5310

Fax: 626-334-5324

 

    	3

    	 

    

 

 

If to the Holder:

 

Vincent J. Davitt

3620 Figueroa St. Glendale, Ca
91206

Tel: 818-667-1422

 

(c)            
Amendments. No amendment, modification or other change to, or waiver of any provision of, this Debenture may be made
unless such amendment, modification or change is set forth in writing and is signed by the Company and the Holder.

 

(d)           
Transfer of Debenture. The Holder may sell, transfer or otherwise dispose of all or any part of this Debenture (including
without limitation pursuant to a pledge) to any person or entity as long as such sale, transfer or disposition is the subject of
an effective registration statement under the Securities Act and applicable state securities laws, or is exempt from registration
thereunder. From and after the date of any such sale, transfer or disposition, the transferee hereof shall be deemed to be the
holder of a Debenture in the principal amount acquired by such transferee, and the Company shall, as promptly as practicable, issue
and deliver to such transferee a new Debenture identical in all respects to this Debenture, in the name of such transferee. The
Company shall be entitled to treat the original Holder as the holder of this entire Debenture unless and until it receives written
notice of the sale, transfer or disposition hereof.

 

(e)            
Lost or Stolen Debenture. Upon receipt by the Company of evidence of the loss, theft, destruction or mutilation
of this Debenture, and (in the case of loss, theft or destruction) of indemnity or security reasonably satisfactory to the Company,
and upon surrender and cancellation of the Debenture, if mutilated, the Company shall execute and deliver to the Holder a new
Debenture identical in all respects to this Debenture.

 

(f)            
Governing Law. This Debenture shall be governed by and construed in accordance with the laws of the State of California
applicable to contracts made and to be performed entirely within the State of California.

 

(g)           
Successors and Assigns. The terms and conditions of this Debenture shall inure to the benefit of and be binding upon
the respective successors (whether by merger or otherwise) and permitted assigns of the Company and the Holder. The Company may
not assign its rights or obligations under this Debenture except as specifically required or permitted pursuant to the terms hereof.

 

(h)            Usury.
This Debenture is subject to the express condition that at no time shall the Company be obligated or required to pay interest
hereunder at a rate which could subject the Holder to either civil or criminal liability as a result of being in excess of
the maximum interest rate which the Company is permitted by applicable law to contract or agree to pay. If by the terms of
this Debenture, the Company is at any time required or obligated to pay interest hereunder at a rate in excess of
such maximum rate, the rate of interest under this Debenture shall be deemed to be immediately reduced to such maximum rate
and the interest payable shall be computed at such maximum rate and all prior interest payments
in excess of such maximum rate shall be applied and shall be deemed to have been payments in reduction of the principal
balance of this Debenture.

 

    	4

    	 

    

 

 

IN WITNESS WHEREOF, the Parties have caused
this Debenture to be signed in their name by a duly authorized officer on the date first above written.

 

 

VIRAL GENETICS, INC.

 

 

By: /s/ Haig Keledjian                   

Name: Haig Keledjian

Title: President

 

 

    	5

    	 

    

 

ANNEX I

 

NOTICE
OF CONVERSION

 

The Company hereby elects to require conversion of
principal of and/or interest accrued on the _% Unsecured Convertible Debenture (the "Debenture") issued by it to
___________________ into shares of common stock ("Shares") of the Company according to the terms and
conditions of the Debenture. Capitalized terms used herein and not otherwise defined shall have the respective meanings set
forth in the Debenture.

 

Date of Conversion:____________________________

 

Principal Amount of

Debenture to be Converted:______________________

 

Amount of Interest

to be Converted:_______________________________

 

Number of Shares of

Common Stock to be Issued:_____________________

 

Name of Holder:_______________________________

 

Address: ___________________________________

 

___________________________________________

 

___________________________________________

 

Signature: ___________________________________

Name:

Title:

 

    	6Exhibit 10.23

 

CONSULTING AGREEMENT

 

THIS
CONSULTING AGREEMENT (the "Agreement'') is made and entered into the 1st day of August, 2010 (the "Effective Date")
by and between VIRAL GENETICS, INC., a Delaware corporation (the "Company"), and SHEEHANBOYCE, LLC, a limited liability
corporation registered in the state of Colorado ("Consultant").

 

(the "Parties")

 

WHEREAS
the Company is an early-stage business engaged in the development of certain biomedical products and Chemical product for
Biofuel industry; and

 

WHEREAS
Consultant has experience, knowledge, contacts, and skills which are beneficial to the development of the Company; and

 

WHEREAS
the Company wishes to engage Consultant and to define the nature of the relationship, to protect certain confidential information
owned or possessed by the Company, and to establish certain other representations, warranties and covenants.

 

NOW
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree
as follows.

 

1) Non-Exclusive
Engagement of Consultant; Term. The Company hereby engages Consultant as its non exclusive provider of the consulting services
described in this Agreement, for a term (the "Term"), which will commence on the Effective Date of this Agreement and
end August 31, 2012.

 

2) Consultant
Services. On the terms and conditions set forth in this Agreement, Consultant will provide the following services to the Company
as directed by the Company (the "Services"):

 

		a)	Consultant agrees to serve
as a scientific advisor to the Company;

		b)	Consultant will advise and assist the Company with the
development, analysis, testing, research, and study of its biomedical technology and other products for the biofuel industry,
including, without limitation, design of clinical trials and relations with regulatory bodies;

		c)	Consultant will advise and
assist the Company with the development of a commercial development strategy for the Company's products in the United States of
America;

		d)	Consultant shall advise and assist the Company with respect
to the publication of reports, results, analyses, studies and other scientific and medical activities of the Company, in recognized
peer reviewed literature;

		e)	Consultant will advise and
assist the Company on other issues with respect to the Company's products;

		f)	Consultant will advise and
assist the Company on increasing the depth and visibility of its advisory board and related infrastructure, including identifying
and assisting with the recruitment of qualified candidates to serve as advisors, consultants, employees or service providers;

		g)	Consultant will assist the
Company in identifying its scientific goals; and

		h)	Consultant will assist and advise the Company in other
areas in which Consultant has expertise as reasonably requested from time to time by the Company.

 

 

    	1

    	 

    

 

3) Method of
Providing Services. It is understood that the Company will not control the manner nor prescribe the method by which the services
under this Agreement are to be performed by Consultant. Consultant shall be available for a teleconference meeting with the management
of the Company at least once per month during the Term. Consultant will perform services, and may communicate with the Company's
management and other parties, through personal meetings, correspondence, telephone or video conferences, and such other methods,
and at such times, as mutually determined, subject to the reasonable convenience of the parties. Unless requested otherwise by
the Company, Consultant shall communicate with the Company's management through the Company's President. Acting in good faith
and consistent with ordinary business practices with respect to advisory relationships, Consultant shall devote a reasonable amount
of time per month to the provision of the Services described herein provided that the other business of Consultant is not materially
affected.

 

4) Performance.
Consultant agrees to at all times faithfully, industriously, and to the reasonable best of their abilities, experience, and talents,
perform all of the duties that may be required of and from them pursuant to the express and explicit terms hereof.

 

5) Independence
of Parties. Nothing contained in this Agreement shall constitute either party as an employee, partner, co-venturer or agent
of the other, it being intended that each shall act as an independent contractor with respect to the other. Consultant is not
authorized to speak on behalf of the Company or bind it in any manner.

 

6) Compensation.

		a)	Shares. For and in
consideration of the agreement of Consultant to enter into this Agreement and as an incentive for the Consultant to use their
best efforts in pursuit of the Company's business, at the end of each three month period during the Term with the first such period
ending October 31, 2010, (each such period, a "Payment Period"), the Company will issue to Consultant at his unilateral
choice either 100,000 shares of the common stock of the Company ("Quarterly Shares") or $1250.00 USD. In the event that
this Agreement is terminated for any reason prior to the end of a Payment Period, the number of Quarterly Shares issuable for
such Payment Period shall be prorated for the elapsed portion of the Payment Period in question, computed by dividing the number
of days from the date of the prior issuance to the effective date of such termination by the total number of days in such Payment
Period and multiplying the fraction so obtained by the amount of the shares due thereunder. Any shares issuable in connection
therewith shall be issued and delivered within ten (1 0) days after the effective date of such termination.

		b)	Benefits, Other Consideration. No benefits, vacation pay,
or other consideration or remuneration of any kind shall be owed to Consultant by the Company, unless specifically referenced
herein. Expenses incurred in Consultant's provision of the Services shall be reimbursed by the Company provided that they are
preapproved in writing by the Company.

 

7) Company Representations
and Warranties. The Company hereby represents and warrants, knowing that Consultant is relying thereon, that:

		a)	The Company is duly organized,
validly existing and in good standing under the laws of the state of Delaware. The Company is qualified to do business as a foreign
corporation in each state in which its business requires it to be so qualified.

		b)	All shares issued to Consultant
under this Agreement will be duly and validly issued, fully paid and non-assessable, and will be delivered free and clear of any
liens, claims or encumbrances, except for restrictions imposed by reference to the registration requirements of the Securities
Act of 1933.

 

8) Consultant
Representations and Warranties. Consultant hereby represents and warrants, knowing that the Company is relying thereon, that:

		a)	Consultant is an Accredited
Investor, as that term is defined in Regulation D in the Securities Act, 1933, and Consultant has completed the attached Schedule
A; and

		b)	Consultant has not in the past, nor will she in the future
engage in any activity contrary to the securities laws of any jurisdiction including, without limitation, those of the United
States of America.

 

 

    	2

    	 

    

 

9) Intellectual
Property, Secrecy. Consultant has read, understood, and accepted the Viral Genetics Intellectual Property Agreement attached
hereto as Schedule B.

 

10) Stock Certificates
and Registration Rights. All shares delivered to Consultant pursuant to this Agreement shall bear a restrictive legend in
the form normally used by the Company for the issuance of restricted shares, and shall be deemed restricted securities under SEC
Rule 144.

 

11)  Changes
to Common Stock. In the event that the Company shall undertake a recapitalization, reverse stock split, forward stock
split, reclassification, or other change to its common stock (a "Change in Common Stock Properties"), the quantity
of shares to be paid to Consultant under Section 5 (a) shall be increased or decreased proportionately, in accordance with
the terms of said Change in Common Stock Properties.

 

12) Extension
and Renewal. The Term may be extended or renewed, and this Agreement may be amended, only by the written agreement of the
parties.

 

13)
Indemnification.

		a)	Each of the Parties hereby
indemnifies and defends the other and each of the their respective officers, directors, employees, shareholders, agents, advisors
or representatives, as applicable, (each, an "Indemnitee") against, and holds each Indemnitee harmless from, any loss,
liability, obligation, deficiency, damage or expense including, without limitation, interest, penalties, reasonable attorneys'
fees and disbursements (collectively, "Damages"), that any Indemnitee may suffer or incur based upon, arising out of,
relating to or in connection with (whether or not in connection with any third party claim):

		i)	any breach of any representation or warranty made by the
other party contained in this Agreement; and

		ii)	the failure of the other party to perform or to comply
with any covenant or condition required to be performed or complied with in accordance with this Agreement.

		b)	Indemnification Procedures for Third Party Claims.

		i)	Promptly after notice to an indemnified party of any claim
or the commencement of any action or proceeding, including any actions or proceedings by a third party (hereafter referred to
as "Proceeding" or "Proceedings"), involving any Damage referred to in this Section, such indemnified party
shall, if a claim for indemnification in respect thereof is to be made against an indemnifying party pursuant to this Section,
give written notice to the indemnifying party, setting forth in reasonable detail the nature thereof and the basis upon which
such party seeks indemnification hereunder; provided, however, that the failure of any indemnified party to give such notice shall
not relieve the indemnifying party of its obligations hereunder, except to the extent that the indemnifying party is actually
prejudiced by the failure to give such notice.

 

    	3

    	 

    

 

 

		ii)	In the case of any Proceeding by a third party against
an indemnified party, the indemnifying party shall, upon notice as provided above, assume the defense thereof, with counsel reasonably
satisfactory to the indemnified party, and, after notice from the indemnifying party to the indemnified party of its assumption
of the defense thereof, the indemnifying party shall not be liable to such indemnified party for any legal or other expenses subsequently
incurred by the indemnified party in connection with the defense thereof (but the indemnified party shall have the right, but
not the obligation, to participate at its own cost and expense in such defense by counsel of its own choice) or for any amounts
paid or foregone by the indemnified party as a result of any settlement or compromise thereof that is effected by the indemnified
party (without the written consent of the indemnifying party).

		iii)	Anything in this Section
13 notwithstanding, if both the indemnifying party and the indemnified party are named as parties or subject to such Proceeding
and either party determines with advice of counsel that there may be one or more legal defenses available to it that are different
from or additional to those available to the other party or that a material conflict of interest between such parties may exist
in respect of such Proceeding, then the indemnifying party may decline to assume the defense on behalf of the indemnified party
or the indemnified party may retain the defense on its own behalf, and, in either such case, after notice to such effect is duly
given hereunder to the other party, the indemnifying party shall be relieved of its obligation to assume the defense on behalf
of the indemnified party, but shall be required to pay any legal or other expenses including, without limitation, reasonable attorneys'
fees and disbursements, incurred by the indemnified party in such defense.

		iv)	If the indemnifying party
assumes the defense of any such Proceeding, the indemnified party shall cooperate fully with the indemnifying party and shall
appear and give testimony, produce documents and other tangible evidence, and otherwise assist the indemnifying party in conducting
such defense. No indemnifying party shall, without the consent of the indemnified party, consent to entry of any judgment or enter
into any settlement or compromise which does not include as an unconditional term thereof the giving by the claimant or plaintiff
to such indemnified party of a release from all liability in respect of such claim or Proceeding. Provided that proper notice
is duly given, if the indemnifying party shall fail promptly and diligently to assume the defense thereof, then the indemnified
party may respond to, contest and defend against such Proceeding and may make in good faith any compromise or settlement with
respect thereto, and recover from the indemnifying party the entire cost and expense thereof including, without limitation, reasonable
attorneys' fees and disbursements and all amounts paid or foregone as a result of such Proceeding, or the settlement or compromise
thereof. The indemnification required hereunder shall be made by periodic payments of the amount thereof during the course of
the investigation or defense, as and when bills or invoices are received or loss, liability, obligation, damage or expense is
actually suffered or incurred.

 

14) Termination.

		a)	Either party may terminate
this Agreement upon not less than 15 days notice in the event of a material breach of this Agreement or material non-performance
by the other party, which breach is not cured within 10 days after the giving of written notice to the breaching party specifying
the circumstances of such breach.

		b)	The Company may terminate this Agreement without further
notice to Consultant in the event that Consultant:

		i)	becomes the subject of an investigation concerning a felony
or a violation of any securities laws;

		ii)	declares bankruptcy;

		iii)	becomes an employee, consultant, officer, director or principal
of a competitor;

		iv)	misrepresents the Company;

 

 

    	4

    	 

    

 

 

		v)	has been grossly negligent
in the performance of duties at least three times in any consecutive 30-day period, and Consultant has been notified in writing
within 5 days of each such occurrence;

		vi)	has engaged in material and
willful or gross misconduct in the performance of duties hereunder; or

		vii)	acts in any other manner
which materially affects the Company in a negative manner.

		c)	Either party may terminate
this Agreement without cause upon 30 days prior written notice to the other party.

 

15) 
Consequences of Termination. Any termination or expiration of this Agreement, whether or not for cause, shall not affect
the obligation of the Company to pay compensation to Consultant that was earned or accrued prior to the date of termination
or expiration. Other than as specifically provided for herein, no further fees or payments of any kind shall be owed to
Consultant upon or following Termination.

 

16) 
Cooperation. The parties shall deal with each other in good faith, good faith meaning honesty in fact and the observance
of all commercial standards of fair dealing and usages of trade, which are regularly observed within the industry.

 

17) No Strict
Construction. The language used in this Agreement shall be deemed to be the language chosen by the parties hereto to express
their mutual intent, and no rule of strict construction shall be applied against any party.

 

18) Arbitration.
In the event of dispute or controversy between the parties as to the performance hereof, this Agreement shall be and remain in
full force and effect and all terms hereof shall continue to be complied with by both parties, it shall be submitted to two arbitrators,
one to be appointed by each, and if those arbitrators do not agree, they shall select a third disinterested and competent person
to act with them, and the decision of the three, or a majority of them, shall be final and conclusive. If either party does not
appoint an arbitrator as aforesaid within 90 days after receipt of notice to the other that it desires arbitration, which notice
shall state the name and address of the arbitrator appointed by such other, and does not within such period furnish to such other
party the name and address of the second arbitrator, then the arbitrator first named shall appoint a disinterested and competent
arbitrator for the party thus defaulting, and the two arbitrators so appointed shall select a third to act with them as aforesaid
and with like effect. Cost of arbitration shall be borne by the parties equally. Judgment upon the reward rendered may be entered
in any court having jurisdiction thereof.

 

19) Governing
Law and Disputes. This Agreement shall be governed by the laws of the State of California, without regard to choice of law
provisions.

 

20) Waiver. Any
party hereto may waive compliance by the other with any of the terms, provisions and conditions set forth herein; provided, however,
that any such waiver shall be in writing specifically setting forth those provisions waived thereby. No such waiver shall be deemed
to constitute or imply waiver of any other term, provision or condition of this Agreement.

 

21) Severability.
If and to the extent that any court of competent jurisdiction holds any provision or any part thereof of this Agreement to
be invalid or unenforceable, such holding shall in no way affect the validity of the remainder of this Agreement.

 

22) Counterpart
and Headings. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all
of which together shall constitute one and the same instrument. All headings in this Agreement are inserted for convenience of
reference and shall not affect its meaning or interpretation.

 

    	5

    	 

    

 

 

23) Entire Agreement.
This Agreement is and shall be considered to be the only agreement or understanding between the parties hereto with respect
to the engagement of Consultant by the Company. All negotiations, commitments, and understandings acceptable to both parties have
been incorporated herein. No letter, telegram, or communication passing between the parties hereto shall be deemed a part of this
Agreement; nor shall it have the effect of modifying or adding to this Agreement unless it is distinctly stated in such letter,
telegram, or communication that it is to constitute a part of this Agreement and is to be attached as a rider to this Agreement
and is signed by the parties to this Agreement.

 

24) Modification
of Contract. This Agreement cannot be modified by tender, acceptance or endorsement of any instrument of payment, including
check. Any words contained in an instrument of payment modifying this contract, including a waiver or release of any claims, or
a statement referring to paying in full is void. This Agreement can only be modified in a separate writing, other than an instrument
of payment, signed by the parties.

 

25) Assignment.
The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto, and their respective heirs,
legal representatives, successors and assigns. This Agreement may not be assigned without the consent of the parties.

 

26) Survival.
The representations, warranties, and agreements of the parties contained in this Agreement will remain operative and in full force
and effect and will survive any termination of this Agreement.

 

27) Notices.
All notices required or permitted under this Agreement shall be in writing and shall be sent by certified or registered first
class mail, return receipt requested, or shall be personally delivered, or sent by an overnight delivery service such as Federal
Express, or shall be transmitted by telefax (provided such telefax message is confirmed by telephonic acknowledgment of receipt
or by sending via other authorized means a confirmation copy of such notice) addressed to the parties at their respective last
known business addresses.

 

Agreed to as of the date affixed hereof.

 

	VIRAL GENETICS, INC.	 	SHEEHANBOYCE, LLC
	 	 	 
	By: /s/     Haig
    Keledjian              	 	/s/ John Sheehan 16 July 2010
	President	 	Joh Sheehan, Principal
	 	 	 

 

 

 

 

 

    	6

    	 

    

 

SCHEDULE A

 

ACCREDITED INVESTOR
QUESTIONNAIRE

 

PERSONAL FINANCIAL INFORMATION.
The following information pertaining to the undersigned as a natural person and U.S. Persons within the meaning of RegulationS
is being provided here in lieu of furnishing a personal financial statement.

 

(a) My individual
net worth, or joint net worth with my spouse, exceeds $1,000,000.

 

	/s/ JS	Yes [  ]	No [x]

 

(b) My individual
income in 2008 and 2009 exceeded $200,000 in each such year, and reasonably expect my individual income will be in excess of $200,000
in 2010.

 

	/s/ JS	Yes [  ]	No [x]

  

(c) The joint income
of my spouse and I in 2008 and 2009 exceeded $300,000 in each such year, and I reasonably expect our joint income will be in excess
of $300,000 in 2010.

 

	/s/ JS	Yes [  ]	No [x]

 

(d) Considering
the foregoing and all other relevant factors in my financial and personal circumstances, am able to bear the economic risk of
an investment in the Company.

 

	/s/ JS	Yes [x]	No [  ]

 

The foregoing is a
true representation of my financial status:

 

/s/ John Sheehan
16 July 2010

John Sheehan

 

SheehanBoyce, LLC

 

    	7

    	 

    

 

SCHEDULE B

 

Viral Genetics Intellectual
Property Agreement

 

(the "Viral Genetics
IP Agreement")

 

In consideration of the undersigned's
initial hire and continued engagement by Viral Genetics, Inc. (the "Viral"), the undersigned (hereinafter the "Consultant")
agrees as follows:

 

1. Non-Solicitation. Consultant
acknowledges that, in the course of performing services for or on behalf of the Company, having access to the Company's technology,
reports, processes, knowledge and know-how, facilities, books and records, or otherwise being associated with the Company, Consultant
may from time to time receive Confidential Information (as defined in Paragraph 2, below) of or with respect to the Company and
hereby stipulates and agrees that such Confidential Information is a part of and essential to the operations and goodwill of the
Company. In connection and in furtherance of the foregoing, Consultant may not (whether directly or indirectly; as the principal
or on such person's own account; or solely or jointly with others as a Consultant, agent, independent contractor, consultant,
general or limited partner, member, stockholder or holder of equity securities of any other person, other than through ownership
of less than one percent of a class of publicly-traded securities of a company) engage in any of the conduct or activity described
below in this Paragraph 1.

 

(a) Consultant
may not, so long as Consultant is a Consultant of the Company and until the third anniversary of the effective date of termination
of Consultant's engagement with the Company for any reason, solicit, induce or influence any person that at such time is (or,
during the six (6) month period ending on the effective date of termination of Consultant's engagement with the Company, was)
a vendor, licensor, licensee, distributor, customer, client, Consultant, or independent contractor of the Company to terminate
any contract or agreement with the Company or leave the service of the Company. Consultant acknowledges that the restrictions
in this subparagraph (a) of this Paragraph I will not impair Consultant's ability to carry on Consultant's profession or earn
a living.

 

(b) Consultant
may not, so long as Consultant is a Consultant of the Company and until the third anniversary of the effective date of termination
of Consultant's engagement with the Company for any reason, without the express prior written consent of the Company, participate
either directly or indirectly in any discussion or negotiation with any person that at such time is (or, during the six month
period ending on the effective date of termination of Consultant's engagement with the Company, was) a vendor, licensor, licensee,
distributor, customer, client, Consultant, or independent contractor of the Company the purpose of which discussion or negotiation
would be materially adverse to the interests of the Company and the relationship existing between the Company and such person.
Consultant acknowledges that the restrictions in this subparagraph (b) of Paragraph 1 will not impair Consultant's ability
to carry on Consultant's profession or earn a living.

 

2. Non-Disclosure
of Information. Consultant understands that the covenants and agreements in this Paragraph 2 may limit Consultant's ability
to earn a livelihood in a business similar to the business of the Company of researching, developing and distributing biomedical
products and technology, but nevertheless believes that Consultant has received and will receive sufficient consideration and
other benefits from the Company so as to clearly justify such restrictions which, in any event (given Consultant's education,
skills and ability), Consultant does not believe would prevent Consultant from earning a living:

 

(a) Consultant
acknowledges that, in the course of performing services for or on behalf of the Company, having access to the Company's technology,
reports, processes, knowledge and know-how facilities, books and records, or otherwise being associated with the Company, Consultant
will have access to, and become acquainted with, Confidential Information of or with respect to the Company and hereby stipulates
and agrees that such Confidential Information is a part of and essential to the operations and goodwill of the Company. Consultant
(i) hereby stipulates and acknowledges that the Confidential Information constitutes important, material, proprietary and confidential
trade secrets of the Company that affect the successful conduct of the business and goodwill of, the Company; (ii) stipulates
and acknowledges that any and all of the Confidential Information is the sole and exclusive property of the Company, regardless
of whether Consultant was engaged in the development of any of such Confidential Information while performing services for or
on behalf of the Company; (iii) agrees to keep all such Confidential Information in strictest confidence, and not to, directly
or indirectly, use or divulge, disclose or communicate to any person (other than a duly-authorized representative of the Company)
any such Confidential Information other than in the ordinary course of business of the Company for the benefit of the Company;
and (iv) agrees not to copy or otherwise duplicate any such Confidential Information or knowingly allow anyone else to copy or
otherwise duplicate such Confidential Information, other than in the ordinary course of business of the Company for the benefit
of the Company. Upon the end of the engagement with Viral, and at any time at the request of the Company, shall promptly return
to the Company all copies of such Confidential Information delivered to or obtained by Consultant or, at the election of the Company,
certify that all copies of such Confidential Information in the possession of Consultant or any person who received such Confidential
Information from Consultant have been destroyed or erased.

 

    	8

    	 

    

 

 

(b) "Confidential
Information" means, with respect to the Company, any technical, financial, or business information (including, without limitation,
manuals, forms, memoranda, reports, journals, test results, correspondence, business plans, customer lists, pricing lists, contracts,
plans or specifications, or the like) that may disclose (or may reasonably be expected to disclose) the customs and practices,
marketing methods and data, services and products, methods of doing business, manner of operation, scientific know-how, formulas,
technical data or information, clinical study protocols, patient or biologic information, manufacturing information or know how,
and other confidential information, regardless of whether in written, oral, graphic, encoded, encrypted, tangible, or intangible
forms, all of which the Consultant hereby acknowledges constitute "trade secrets" within the meaning of the Uniform
Trade Secrets Act, codified at sections 3426 et seq. of the California Civil Code.

 

(c) Consultant
shall have no obligation to preserve the confidential or proprietary nature of any information that (i) was already known to Consultant
free of any obligation to keep such information confidential at the time of disclosure of such information; (ii) is or becomes
publicly known through no wrongful act of Consultant; (iii) is rightfully received from a third person having no direct or indirect
secrecy or confidentiality obligation to the Company; (iv) is disclosed to a third person by the Company without restrictions
on confidentiality similar to those contained in this Paragraph 2; (v) is approved for disclosure by written authorization of
the Company; or (vi) is a Prior Invention (as defined in Paragraph 3).

 

(d) The obligations
of Consultant under this Paragraph 2 shall also extend to Consultant's affiliates and Consultant shall, upon reasonable request
of the Company, advise each such person in writing of the obligations imposed on such person under this Paragraph 2. "Affiliate"
means: (i) the Consultant's current spouse, siblings, lineal ancestors (including those by adoption), and lineal descendants (including
those by adoption), and spouses of the foregoing ("Family Members"); and (ii) any corporation, partnership, trust, or
limited liability company in which the Consultant or any Family Member is an officer, director, manager, trustee, general partner,
or holder of one percent or more the outstanding voting securities, capital or profits interests, or beneficial interests, s applicable.

 

(e) The provisions
of this Paragraph 2 shall apply to Consultant throughout the term of engagement and continue in perpetuity.

 

3. Assignment of
Inventions. Consultant shall promptly disclose any Consultant Creations (as defined below) to the Company and any such Consultant
Creations shall be the Company's sole property. All original works of authorship that are made by Consultant (in whole or in part,
either alone or jointly with others) within the scope of Consultant's engagement with the Company and that are protectable by
copyright are "works made for hire" as defined in the United States Copyright Act (17 U.S.C.A. section 101). "Consultant
Creation(s)" means any idea, concept, discovery, development, device, design, apparatus, use, machine, practice, process,
method, product, composition of matter, improvement, formula, algorithm, literary or graphical or audiovisual work or sound recording,
mask work, or computer program of any kind (whether or not subject to patent, copyright, trademark, trade secret, mask work right,
or similar protection) that relate(s) in any way to any of the Company's biological or pharmaceutical products under investigation
or development from time to time, or any manufacturing or production know-how, scientific know-how, processes, or procedures pertaining
thereto that are conceived, suggested, reduced to practice, or devised by Consultant, in whole or in part, either solely or jointly
with others, during Consultant's engagement with the Company or using the Company's facilities, or equipment or using Confidential
Information.

 

    	9

    	 

    

 

(a) Consultant
hereby assigns to the Company, and agrees to assign to the Company in the future where appropriate, any and all such Consultant
Creations, and agrees to cooperate with the Company in the execution of appropriate instruments assigning and evidencing such
assignment and ownership rights of the Company, to the maximum extent permitted by section 2870 of the California Labor Code.
In order that the Company may perfect and protect its rights to Consultant Creations as provided hereunder, Consultant agrees
that Consultant's obligations regarding assignment of such Consultant Creations to the Company shall survive termination of Consultant's
engagement with the Company for a term of one year following the date of termination for any reason. Consultant hereby acknowledges
that the Company has provided to Consultant the text of section 2870 of the California Labor Code, and, concurrently with the
execution of this Agreement, Consultant has executed and delivered to the Company a copy of Exhibit A attached hereto acknowledging
that the Company has provided to Consultant written notification regarding section 2870 of the California Labor Code.

 

(b) If any Invention
related to the subject matter of Consultant's engagement with the Company was made, conceived, developed or first reduced to practice
by Consultant (in whole or in part, either alone or jointly with others) prior to Consultant's engagement with the Company, it
is listed on Exhibit B ("Prior Inventions"). Consultant retains the right to use, enhance, license and/or authorize
others to use for any purpose or application (a) the Prior Inventions or (b)other Inventions developed by Consultant that are
unrelated to the Consultant's engagement with the Company, unrelated in any way to any of the Company's biological or pharmaceutical
products under investigation or development from time to time (or any manufacturing or production know-how, scientific know-how,
processes, or procedures pertaining thereto), and developed by Consultant outside the scope of her engagement with the Company.

 

4.
Enforcement. Consultant acknowledges that the covenants and the restrictions contained in this Agreement are necessary and
required for the adequate protection of the Company and are necessary to preserve the goodwill of the Company and the value of
its existing Confidential Information, inventions, contracts and relationships; such covenants relate to matters that are of a
special, unique and extraordinary character that give each of such covenants or restrictions a special, unique and extraordinary
value; and, a breach of any such covenant or restriction will result in loss of goodwill, invasion of property rights of the Company,
unfair competition by the breaching party, and other irreparable harm and damages to the Company, which cannot be adequately compensated
by a monetary award. It is accordingly agreed that the Company or any of its subsidiaries (without posting bond or other security
and without the necessity of proving actual damages) shall be entitled to an injunction or injunctions to prevent breaches of
this Agreement and to enforce specifically the terms and provisions of this Agreement. Nothing in this Agreement shall be construed
as prohibiting the Company from pursuing any other legal or equitable remedies available to the Company for such breach or threatened
breach of any of the provisions of this Agreement (including, without limitation, recovery of all damages from Consultant and
an equitable accounting of all earnings, profits and other benefits arising from such violation). If Viral instigates any suit
or proceeding to enforce this Agreement against Consultant and Viral prevails, the Consultant shall reimburse the Company for
its costs and expenses incurred therein, including costs of appeal and enforcement and reasonable attorneys' fees.

 

AGREED:

 

	CONSULTANT	 	 
	 	 	 
	/s/ John Sheehan         	DATED: 16 July 2010              	 
	John Sheehan	 	 
	 	 	 
	SheehanBoyce, LLC	 	 

 

 

 

    	10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]